checkpoint inhibitors

August 22, 2019

New prostate cancer treatment concept

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

By Leigh MacMillan
July 22, 2019

Encephalitis identified as rare toxicity of immunotherapy treatment

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

By Tom Wilemon
Young Kim, MD, PhD, left, Michael Korrer, PhD, and colleagues are studying a potential new cancer immunotherapy option.
February 21, 2019

Discovery points to new cancer immunotherapy option

An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

By Leigh MacMillan
December 13, 2018

Breast cancer-killing RIG

A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer.

By Leigh MacMillan
November 15, 2018

Immunotherapies linked to specific heart complications

In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

By Tom Wilemon
September 13, 2018

Study tracks incidence, timing of immunotherapy-related deaths

Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.

By Tom Wilemon